Mauna Kea Technologies Overview
Pro stress-test →Mauna Kea Technologies manufactures and sells Cellvizio, the real-time in vivo cellular imaging platform that uniquely delivers in vivo cellular visualization enabling physicians to monitor disease progression and assess reactions as they happen in real time. The company offers a range of medical devices for gastroenterology, pulmonology, and urology applications.
Strategic Profile
Pro stress-test →The company has obtained regulatory approvals to commercialize its Cellvizio system in Switzerland and the United Kingdom, providing access to strategic European markets recognized for excellence in interventional gastroenterology. Recent organizational changes announced in February 2026 aim to accelerate growth outside the United States by structuring international expansion of both Cellvizio and CellTolerance programs.
Competitive Landscape
Pro stress-test →Mauna Kea specializes in optical biopsy devices designed for visualizing and detecting cellular abnormalities during gastrointestinal and pulmonary endoscopic procedures, primarily in cancer patients. The company competes in the medical imaging and diagnostic space with differentiated real-time cellular visualization technology but operates in a niche market with limited direct competitors.
Industry Context
Mauna Kea Technologies operates in Medical Devices - Diagnostic Imaging and Endomicroscopy.
Key facts
Founded: 2000 · Headquarters: Paris, France · Revenue: $9M · Market cap: $27.4M